argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
| Revenue (TTM) | $5.92B |
| Gross Profit (TTM) | $3.54B |
| EBITDA | $1.90B |
| Operating Margin | 36.30% |
| Return on Equity | 23.60% |
| Return on Assets | 11.60% |
| Revenue/Share (TTM) | $3.80 |
| Book Value | $5.38 |
| Price-to-Book | 6.69 |
| Price-to-Sales (TTM) | 9.51 |
| EV/Revenue | 9.02 |
| EV/EBITDA | 27.58 |
| Quarterly Earnings Growth (YoY) | 50.60% |
| Quarterly Revenue Growth (YoY) | 52.10% |
| Shares Outstanding | $62.89M |
| Float | $1.56B |
| % Insiders | 0.00% |
| % Institutions | 46.11% |
Volatility is currently contracting
NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE (“argenx” or the “Company”) (NASDAQ: ARGX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
November 3, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), the immunology innovation company, today announced that members of the management team will participate in the following investor conferences in November: Guggenheim 3rd Annual Healthcare Innovation Conference. Fireside chat on Tuesday, November 10 at 2:00 p.m.
NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE ("argenx" or the "Company") (NASDAQ: ARGX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Product net sales reached $1.7 billion, growing 54% year over year. Operating profit reached $486 million with a 28% operating margin.
argenx SE ( ARGX ) Q3 2026 Earnings Call October 22, 2026 8:30 AM EDT Company Participants Beth DelGiacco Karen Massey - CEO & Executive Director Karl Gubitz - Chief Financial Officer Sandrine Piret-Gerard - Chief Commercialization Officer Luc Truyen - Chief Medical Officer Conference Call Participants Daniel Giraldo Perez - BofA Securities, Research Division Derek Archila - Wells Fargo Securities, LLC, Research Division Victor Floch - BNP Paribas, Research Division Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division Akash Tewari - Jefferies LLC, Research Division Yaron Werber - TD Cowen, Research Division Yatin Suneja - Guggenheim Securities, LLC, Research Division Alexander Thompson - Stifel, Nicolaus & Company, Incorporated, Research Division Danielle Brill Bongero - Truist Securities, Inc., Research Division Myles Minter - William Blair & Company L.L.C., Research Division Rajan Sharma - Goldman Sachs Group, Inc., Research Division Jing Deng Sean Laaman - Morgan Stanley, Research Division Sophia Graeff Buhl Nielsen - JPMorgan Chase & Co, Research Division Luca Issi - RBC Capital Markets, Research Division Douglas Tsao - H.C.
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now?
argenex NASDAQ: ARGX reported third-quarter 2026 product net sales of $1.7 billion, up 54% from a year earlier and 13% sequentially, as patient growth in generalized myasthenia gravis, or MG, and chronic inflammatory demyelinating polyneuropathy, or CIDP, continued to support demand for VYVGART.
October 15, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that it will host a conference call and audio webcast on Thursday, October 22, 2026 at 2:30 PM CET (8:30 AM ET) to discuss its third quarter 2026 financial results and provide a business update.
ARGX's FB102 achieves its primary endpoint in a phase II celiac disease study, paving the way for late-stage development despite a nearly 12% stock drop.
argenx shares tumble 12% after discontinuing its late-stage Sjogren's disease study, while positive FB102 data in celiac disease offer a contrasting pipeline development.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ARGX and any ticker you trade — then tracks every position and per-strategy win rate.
